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Lymphatic is a prerequisite for the maintenance of tissue ﬂuid balance and immunity in the body. A body of evidence also shows
that lymphangiogenesis plays important roles in the pathogenesis of diseases such as tumor metastasis and inﬂammation. The
eye was thought to lack lymphatic vessels except for the conjunctiva; however, advances in the ﬁeld, including the identiﬁcation
of lymphatic endothelial markers (e.g., LYVE-1 or podoplanin) and lymphangiogenic factors (e.g., VEGF-C), have revealed
the exsitence and possible roles of lymphatics and lymphangiogenesis in the eye. Recent studies have shown that corneal
limbus, ciliary body, lacrimal gland, orbital meninges, and extraocular muscles contain lymphatic vessels and that the choroid
might have a lymphatic-like system. There is no known lymphatic outﬂow from the eye. However, several lymphatic channels
including uveolymphatic pathway might serve the ocular ﬂuid homeostasis. Furthermore, lymphangiogenesis plays important
roles in pathological conditions in the eye including corneal transplant rejection and ocular tumor progression. Yet, the role of
lymphangiogenesis in most eye diseases, especially inﬂammatory disease or edema, remains unknown. A better understanding of
lymphatic and lymphangiogenesis in the eye will open new therapeutic opportunities to prevent vision loss in ocular diseases.
1.Introduction
The lymphatic system in human was ﬁrst described by
Gasper Aselli in 1627 in a paper “De Lacteibus sive Lacteis
Venis,” Quarto Vasorum Mesarai corum Genere novo in-
vento. Now, it is well known that the lymphatics remove
interstitial ﬂuid and macromolecules, including proteins,
and transport them to lymph nodes before entering the
blood circulation. From the lymphatic capillaries, the lymph
is transported via precollectors to collecting lymphatic ves-
sels and is returned through the lymphaticovenous junctions
between the thoracic or lymphatic duct and the subclavian
veins to the blood circulation [1]. Another role of the ly-
mphatics is to carry immune cells to the lymph nodes and to
control the immunity in health and disease.
Although the presence of lymphatics was long known
through histology [2], systematic lymphatic research started
later than blood vessels because of lack of speciﬁc mark-
ers. Recent identiﬁcation of lymphatic endothelial markers
facilitated lymphatic research [3, 4]. Furthermore, ﬁnding
of lymphangiogenic factors reveals various mechanisms
of lymphangiogenesis in health and disease. For instance,
lymphangiogenesis plays critical roles in various disorders,
including cancer metastasis and inﬂammation [5, 6].
In the past two decades, lymphatics and lymphangio-
genesis in the eye and the phenotypes in the various ocular
diseaseshavebeeninvestigated.Histologicalstudiesshowthe
location and existence of lymphatics in the eye [7]. These
studieshaverevealedthatlymphaticscontributetotheocular
homeostasis and that ocular lymphangiogenesis may play
important roles in eye disorders. This paper reviews current
knowledge on lymphatics and lymphangiogenesis in the eye
and discusses the possibility of lymphatic-targeting therapy.
2. VEGF/VEGFRSystem inLymphangiogenesis
VEGF family is important for vasculogenesis, angiogenesis,
and lymphangiogenesis [8]. The mammalian VEGF family2 Journal of Ophthalmology
presently contains ﬁve members: VEGF-A, placenta growth
factor (PlGF), VEGF-B, VEGF-C, and VEGF-D. VEGF-A has
important roles in mammalian vascular development and
in diseases involving abnormal growth of blood vessels. Re-
cent clinical studies have demonstrated the signiﬁcance of
VEGF-A in ocular neovascularization (e.g., diabetic retino-
pathy and aged-macular degeneration) with use of VEGF-A
neutralizing antibodies [9]. VEGF-C and VEGF-D are main
lymphangiogenic factors in both physiological and patho-
logical conditions. The VEGF receptor family contains three
members: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and
VEGFR-3 (Flt-4). VEGF-A binds and activates two tyrosine
kinase receptors: VEGFR-1 and VEGFR-2 [8]. VEGF-A does
not show any appreciable binding aﬃnity to VEGFR-3.
VEGFR-3 is a ligand for VEGF-C and VEGF-D. Mature form
ofVEGF-CandhumanVEGF-D areknowntobindandacti-
vate VEGFR-2 [10, 11]. Various studies clarify the involve-
ment of VEGF-C and -D/VEGFR-3 system in cancer lym-
phatic invasion and lymph node metastasis [12, 13]. Fur-
thermore VEGF-C and -D/VEGFR-3 signaling is involved in
inﬂammatory diseases and organ transplantation [6, 14, 15].
3. The Other Lymphangiogenesis-Related
Factors
Lymphangiogenic factors include not only VEGF family but
also the other growth factors and cytokines such as insulin-
like growth factors (IGFs), hepatocyte growth factor (HGF),
ﬁbroblast growth factors (FGFs), and interleukins (ILs).
These growth factors and cytokines have been well known to
be angiogenic. Some of these factors can cause lymphangio-
genesis directly and some can induce lymphangiogenesis via
VEGFfamilyindirectly.Theseﬁndingsareshownwithassays
in cornea.
4.CornealAvascularityand
Its Alymphatic Characteristics
The normal cornea, but not the conjunctiva, is devoid of
lymphatic vessels as well as blood vessels (Figure 1). The
alymphatic mechanism was unknown until recently a study
showed that a soluble VEGFR-2 form is secreted by corneal
epithelial cells selectively suppressing the physiologic growth
of lymphatics [16]. This ﬁnding is the ﬁrst identiﬁcation of a
speciﬁc lymphangiogenesis inhibitor.
5. Corneal Lymphangiogenesis Assay
Because of its avascularity, the cornea is widely used to inves-
tigate lymphangiogenesis. One of the most reliable methods
to examine lymphangiogenesis is corneal inﬂammation
model by suture or alkali burn (NaOH solution) [17, 18]
(Figure 2). Another authentic method is cornea micropocket
assay, which has been used for estimation of angiogenesis
since the 1970s [19, 20]( Figure 2). In both models, lym-
phangiogenesis occurs from preexisting limbal lymphatics.
Thecorneamicropocketmodelhasrevealedthatmostangio-
genic factors also induce lymphangiogenesis (Table 1). This
might indicate that the mechanism of lymphangiogenesis is
partially similar with angiogenesis. IGF-1 and IGF-2, which
signiﬁcantly stimulates proliferation and migration of lym-
phatic endothelial cells, can induce corneal lymphangiogen-
esis. IGF-1-induced lymphangiogenesis is not mediated by
VEGFR-3 signaling [21]. A potent angiogenic factor, VEGF-
A, is also shown to be a lymphangiogenic factor in mouse
cornea [22]. In VEGF-A-induced lymphangiogenesis, there
are both mechanisms: VEGFR-3-dependent and VEGFR-
3-independent. VEGF-A can induce the proliferation of
lymphatic endothelial cells directly, which is not mediated
by VEGFR-3 [23]. This lymphangiogenesis is also mediated
by macrophage-derived VEGF-C with the inﬂammatory
suture model [24]. The balance between direct and indirect
eﬀect in VEGF-A-induced lymphangiogenesis may depend
on the situations. VEGF-C, a potent lymphangiogenic factor,
was conﬁrmed to induce corneal lymphangiogenesis [25].
VEGF-C156S, which is a speciﬁc ligand for VEGFR-3, also
causes lymphangiogenesis as well as angiogenesis in the
cornea [26]. This VEGFR-3-mediated lymphangiogenesis
could be induced by direct eﬀect for lymphatic endothelium
as well as macrophage recruitment. Platelet-derived growth
factor (PDGF) causes corneal lymphangiogenesis via direct
stimulation of lymphatic endothelium [27]. HGF also causes
corneal lymphangiogenesis that can be blocked by VEGFR-
3 inhibition partially [28]. FGF-2, which is a well-known
potent angiogenic factor, could cause lymphangiogenesis
with corneal micropocket assay [29]. The FGF-2-induced
lymphangiogenesiswasblockedbyVEGFR-3inhibition[29].
These investigations suggest that each GF (growth factor)
hasdiﬀerentdependencyonVEGFR-3signalinginlymphan-
giogenesis. Some GFs cause proliferation or migration of
lymphatic endothelial cells directly, whereas some GFs
upregulate VEGF-C/-D to activate VEGFR-3 in lymphangio-
genesis. Interestingly, the corneal micropocket assay reveals
that low dose of FGF-2 causes selective lymphangiogenesis
[30]. This observation provides the evidence that lymphatic
growthispossiblewithoutangiogenesis.However,thedetail-
ed mechanism of FGF-2-mediated lymphangiogenesis has
been enigmatic. A recent examination using mouse cornea
introduced physiological expression of lymphatics without
the presence of blood vessels, which is an indication that
angiogenesis and lymphangiogenesis might occur indepen-
dently [25]. In the study, FGF-2-deﬁcient mice show sig-
niﬁcantly less preexisting lymphatic sprouts without having
an eﬀect on angiogenesis in the cornea compared to their
wild-type counterparts [25]. Consequently, this suggests that
lymph- and angiogenesis might occur independently.
6. GeneticHeterogeneityof Lymphangiogenesis
Recently two diﬀerent groups have reported on genetic he-
terogeneity of corneal lymphangiogenesis in diﬀerent mouse
strains with the corneal suture model and the corneal micro-
pocket model independently [25, 34]( Figure 3). This sug-
gests that heterogeneity of corneal lymphatics shows diﬀer-
ent inﬂammatory reactions in patients. In the comparative
analysis of lymphatics with various strains, nu/nu mice,
which have a greatly reduced number of T cells, showedJournal of Ophthalmology 3
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Figure 1: Distributionof lymphatics in theeye. Immunological staining withlymphatic speciﬁc markers as well as histological examinations
has revealed the distribution of lymphatic vessels in the eye. Conjunctiva is well known to possess lymphatics. Cornea limbus, ciliary body,
lacrimal gland, orbital meninges and extraocular muscle also contain lymphatic vessels, and choroid might have lymphatic-like system.
Cornea, retina, and optic nerve do not show lymphatics. Intraocular lymphatic can be observed only in the ciliary body. (A), (B), and (C)
show the details of corneal limbal area, angulus iridocornealis, and optic nerve, respectively. Red indicates lymphatic vessels.
Table 1: Growth factors and cytokines in corneal lymphangiogenesis assay. Various growth factors or cytokines induce lymphangiogenesis
as well as angiogenesis with or without VEGFR-3 activation.
Growth factor/cytokine Angiogenesis Lymphangiogenesis Via VEGFR-3 Reference
VEGF-A (160–200ng) ++ +/− Yes/No [22–24]
VEGF-A (400ng) ++ + ? [31]
VEGF-C (160–400ng) + +/++ Yes [22, 25]
VEGF-C156S (80ng) + + Yes [26]
FGF-2 (12.5ng) − +Y e s [ 30]
FGF-2 (80–100ng) ++ ++ Yes [29]
HGF (280ng) + + Yes [28]
PDGF-BB (320ng) + + No [27]
IGF-1 (1μg) + + No [21]
IL-1β (30–50ng) + + Yes [32, 33]4 Journal of Ophthalmology
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Figure 2: Mouse cornea lymphangiogenesis model. No lymphatic vessels exist in the normal mammalian cornea. Implantation of growth
factor or cytokine into a surgically created micropocket in the mouse cornea stroma (a) or corneal injury by suture (b) induces lymphan-
giogenic response. Corneal lymphangiogenesis as well as angiogenesis can be examined 6 or 7 days after pellet implantation or suture,
respectively (a) and (b). Double staining of corneal ﬂat mounts for lymphangiogenic (LYVE-1, red) endothelium and angiogenic (CD31,
green) with immunohistochemistry (c).
similar lymphatic development and GF-induced lym-
phangiogenesis with the other strains, suggesting that T
cells might be unnecessary for lymphatic development as
well as GF-induced lymphangiogenesis in the cornea [25]
(Figure 3). Inﬂammation model by suture has also revealed
various insights of lymphangiogenesis. After corneal inﬂam-
mation, pathologic corneal lymphangiogenesis can regress
earlier than angiogenic vessels [17].
7. The Interplay between Angiogenesis and
Lymphangiogenesis
As described above, lymphangiogenesis and angiogenesis
occurinconcert[6].However,howbloodandlymphaticves-
sels regulate each other has been unknown. Recently, it was
reported that angiogenic vessels delay lymphangiogenesis
using corneal micropocket assay [31]. In response to VEGF-
A, corneal lymphatics grow with a delay compared to
blood vessels. Higher concentrations of VEGF-A are needed
for lymphangiogenesis than for angiogenesis. The poised
temporal and spatial association of angio- and lymphan-
giogenesis indicates interdependencies between blood and
lymphaticvessels.ProteolyticallyprocessedVEGF-Cbindsto
andactivatesVEGFR-2.UpregulatedVEGFR-2inangiogenic
tips could trap VEGF-C, and the trapped VEGF-C could
not reach lymphangiogenesis due to the distance apart
from the lymphatic vessels [31]. This VEGF-C/VEGFR-2
interaction might regulate the relation between angio- and
lymphangiogenesis. Delayed lymphangiogenesis might allow
immune cells additional time at the inﬂammatory sites be-
cause immune cells originate from angiogenic vessels and
drainaed through lymphangiogenic vessels [35].
8. Macrophages in Lymphangiogenesis
Macrophages have been well investigated for their role in ne-
ovascularization in various ocular diseases including ker ati-
tis [36, 37], retinal angiogenesis [38, 39], and choroidal neo-
vascularization [40, 41]. Macrophages contribute to corneal
lymphangiogenesis in two diﬀerent ways. Maruyama et al.
showedthatCD11b(+)macrophagesinﬁltratetheinﬂamma-
tory cornea and transdiﬀerentiate into lymphatic endothe-
lium that contributes to lymphangiogenesis [42]. Another
role of macrophages is to provide lymphangiogenic factors.
During corneal inﬂammation, inﬁltrating macrophage ac-
tivates the NF-κB signaling and secretes the downstream
cytokines (e.g., VEGF-A, -C, and -D) to induce corneal lym-
phangiogenesis [32]. NF-κB inhibition could block corneal
lymphangiogenesis as well as the angiogenesis. A recent
papershowedamechanismformacrophagestoinﬁltrateinto
the sites of corneal lymphangiogenesis. Vascular adhesion
protein-1 (VAP-1) is an endothelial glycoprotein that reg-
ulates leukocyte transmigration [43, 44]. VAP-1 inhibition
blocksinﬂammatorycorneallymphangiogenesisbyreducingJournal of Ophthalmology 5
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Figure 3: Strain-dependent limbal lymphatics. Genetic background signiﬁcantly aﬀects corneal preexisting limbal lymphatics. The area
of preexisting lymphatics in C57BL/6 mice is signiﬁcantly larger than that in Balb/c mice. nu/nu mice show the intermediate phenotype.
Preexisting limbal lymphatics may be heterogenic in patients, causing diﬀerences in corneal transplant rejection or keratitis. nu/nu mice
develop normal lymphatics, suggesting that T cells may not be important for lymphatic development.
Table 2: Lymphatic-associated ocular diseases. The list shows several diseases of the eye that are related to lymphatics or lymphangiogenesis.
Further investigation might provide evidence of the contribution of lymphatics or lymphangiogenesis in the other eye diseases.
Eye diseases Possible role of lymphatics Reference
Corneal transplant Lymphatic vessels but not angiogenic vessels are important for the immune rejection [50]
Dry eye Dry eye, which is a low-grade corneal inﬂammatory disorder, induces lymphangiogenesis [49]
HSV-1 keratitis Corneal herpes simplex virus-1 infection induces lymphangiogenesis via VEGF-A [48]
Glaucoma “Uveolymphatic pathway”; lymphatics exists in the ciliary body [51]
Intraocular tumors “Tumor-associated lymphangiogenesis” correlates the malignancy [52, 53]
macrophage inﬁltration [33]. Macrophage polarization (M1
classical versus M2 alternatively activated macrophages) was
recentlydiscoveredtoregulatevariousinﬂammatorydiseases
[45]. The number of M2 marker(+) macrophages in inﬂam-
matory corneas of VAP-1-inhibitor-treated mice was signif-
icantlylowerthaninvehicle-treatedmice[33].Thus,M2ma-
crophages might play an important role in corneal lymphan-
giogenesis. However, further investigation will be necessary
to discern the role of macrophage polarization in lym-
phangiogenesis. VAP-1 may become a therapeutic target for
various lymphangiogenesis-related ocular diseases. Further-
more, a recent report showed that the antiangiogenic factor
Thrombospondin-1 (TSP-1) is also an endogenous antilym-
phangiogenic factor [46]. TSP-1 can suppress macrophage-
derived VEGF-C and VEGF-D by ligating CD36 on the cells.
As a result, TSP-1 can become a therapeutic molecule for
corneal lymphangiogenesis.
9. Lymphangiogenesis in CornealDisorders
Human cornea lacks lymphatic vessels during the develop-
ment [47]. Vascularization in cornea disturbs visual acuity,
whereas corneal lymphangiogenesis cannot. However, lym-
phangiogenesis in the cornea can modulate corneal immu-
nity or inﬂammation. Increasing studies on lymphatic and
lymphangiogenesis, have shown that lymphatic vessels play
an important role for various corneal disorders (Table 2).
Herpes simplex virus-1 (HSV-1) infection in the cornea
is a leading cause of blindness. Corneal HSV-1 infection
induces lymphangiogenesis, and the corneal lymphatics
persist past the resolution of infection (Table 2). HSV-1-
elicitedlymphangiogenesiswasreportedtobestrictlydepen-
dent on VEGF-A/VEGFR-2 signaling but not on VEGFR-
3 ligands [48]. A recent study also showed that dry eye,
a low-grade corneal inﬂammatory disorder, induces lym-
phangiogenesis by the upregulation of VEGFs and VEGFRs
and CD11b(+) macrophage recruitment. Interestingly, cor-
neal lymphangiogenesis in dry eye does not accompany
angiogenesis (Table 2). However, the mechanism is not fully
appreciated, and further investigation must include the esti-
mation that lymphangiogenesis can be a therapeutic target
for dry eye disease [49].
10. The Role of Lymphangiogenesis in
Corneal GraftRejection
Thecriticalroleoflymphnodesincornealalloimmunization
and graft rejection has been well investigated [54]. VEGFR-3
blockade suppressed corneal antigen-presenting cell traﬃck-
ing to the lymph node and delayed the rejection of corneal6 Journal of Ophthalmology
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Figure 4: Lymphangiogenesis as a possible therapeutic target for the eye diseases. Corneal transplant, glaucoma, and intraocular tumors
were suggested to be related to lymphatics or lymphangiogenesis in the pathogenesis. If choroid has lymphatic function, lymphatics or
lymphangiogenesis may be important for the pathology of uveitis, choroidal neovascularization, or macular edema because of the vital role
of lymphatics in inﬂammation or tissue edema. Red: lymphatic vessels. Green: blood vessels.
transplanted graft rejection [55]. Lymphatic vessels, but not
angiogenic vessels, could be important for immune rejection
after corneal transplantation [50]( Table 2). Lymphatics and
lymphangiogenesis-related factor would be a therapeutic
target for corneal graft rejection (Figure 4).
11. ConjunctivalLymphatics in
Glaucoma Surgery
Conjunctiva is the most lymphatic-developed tissue in the
eye. A surgeon incidentally ﬁlls anesthetic solution into the
lymphatics of a patient’s conjunctiva during an operation.
The doctor routinely visualizes conjunctival lymphatic ves-
sels with a dye to decide where to make scleral ﬁlter to
lowerintraocularpressure(IOP)inglaucomapatients.Inter-
estingly, he suggests that a healthy lymphatic system in the
conjunctivamaydecidetheoutcomeofloweringIOPsurgery
and alerts that mitomycin or cauterization can cause damage
to the lymphatic structures [56].
12. Lymphangiogenesis in Conjunctivitis
Various studies with LYVE-1 or podoplanin antibody con-
ﬁrmed that lymphatic vessels exist in conjunctiva in var-
ious species. Corneal lymphangiogenesis is sprouted from
limbal lymphatics that connect to conjunctival lymphatic
[57]. The removal of conjunctiva could not aﬀect GF-in-
duced corneal lymphangiogenesis, suggesting that the con-
junctiva, including its LYVE-1(+) lymphatics and cells, may
not be necessary for corneal lymphangiogenesis [25]. How-
ever, lymphatics might play an important role to heal con-
junctivitis or conjunctival chemosis, or probably corneal
edema. Furthermore, a group reported that injected tracers
in the anterior chamber or the vitreous utilize conjunctival
lymphatics to reach the lymph nodes [58, 59]. These data
alert that intraocular drug injection aﬀects the immunity.
13. The Possibilityof Lymphatic-Targeting
Therapy in Retinal Disorders
Retina is part of the central nervous system (CNS) that is
vascularized and has been thought not to have lymphatics as
well as other parts of the CNS like the brain [60]. In addition
to severe vision loss, macular edema is commonly associated
with many retinal diseases including diabetic macular edema
and retinal vein occlusion [61]. It is believed to be caused
by hyperpermeability of the retinal vessels and/or decreased
eﬄux of ﬂuid across the retinal pigment epithelium, which
can be induced by outer/inner blood retinal barrier dysfunc-
tion. In the past decade, there were advances in therapy for
macular edema. Administration of steroid or VEGF neutra-
lizing antibodies or vitrectomy can reduce macular edema
signiﬁcantly in patients [62]. However, these treatments may
cause adverse eﬀects including an increased incidence of IOPJournal of Ophthalmology 7
elevation or tractional retinal detachment [63, 64]. These
pharmacological mechanisms to reduce macular edema
must be caused by the blockade of leakage from retinal
vessels [65–67]. However, the mechanism to absorb leaked
interstitial ﬂuid in macular edema is unclear. A recent paper
suggested that drainage from the vitreous might exist via
conjunctival lymphatics [59]. Furthermore, as described
below, choroid might have lymphatic-like system. It has been
reported that the dysfunction of lymphatic vessels causes
lymphedema or tissue edema in various diseases and that
lymphatic normalization or newly lymphatic vessels reduce
tissue edema in the skin [68]. Further investigations of the
lymphatic role of the posterior eye segment may reveal novel
ways to manage macular edema (Figure 4).
Recently podoplanin is shown to be expressed in retinal
pigment epithelium (RPE) [69]. Podoplanin depletion with
siRNA reduces cell aggregation, proliferation, and the tight
junction. RPE regulates outer blood-retinal barrier, which is
broken down in various retinal diseases. Further research is
required to reveal how podoplanin in RPE contributes to the
pathogenesis of retinal disorders.
14. Choroidal Lymphatics:
A ControversialPoint
The choroid, which forms the uvea with the ciliary body and
the iris, is one of the most highly vascularized tissue in the
body. The choroid provides oxygen and nourishment to the
outer layers of the retina. Before the discoveries of lymphatic
speciﬁcmarkers,varioushistologicalexaminationsofanimal
choroid have shown the existence of lymphatic vessels in
the choroid (Figure 1). In 1997, a paper on the avian
eye proposed that the lacunae of the choroid represented
a system with short lymphatic vessels that reached the
choriocapillaris [70]. The authors proposed that the system
might drain intraocular ﬂuids directly into the eye venous
system. In 1998, W. krebs ad I. P. krebs showed evidence of
choroidal lymphatic vessels in the monkey by using electron
microscopy [71]. In this paper, their observation with lym-
phatic speciﬁc features, including the lack of a continuous
external basement lamina and the presence of anchoring
ﬁlaments, supported their conclusion. Another study exam-
ined whether lymphatic vessels existed in monkey choroid
[72].Thiselectronmicroscopicstudyobservedthelymphatic
sinus-like structures in the outer choroid. The lymphatic
sinus-like structures were lined with ﬁbroblast-like cells with
large intercellular gaps and contained amorphous material,
which was probably tissue ﬂuid. Furthermore, this study
indicated that the cells lining the lymphatic sinus-like struc-
turesputoutvalve-likecytoplasmicprocessesintothelumen.
However, this study also pointed out that the ultrastructure
in the outer choroid diﬀered from typical lymphatics in the
point of the discontinuous cell lining with large gaps.
Lymphatic vessel endothelial hyaluronic acid receptor
(LYVE-1) is widely accepted as the most reliable lym-
phatic marker that is also expressed by a subpopulation of
macrophages [4, 42]. A recent paper on human choroid
checked for lymphatic vessels with immunohistochemistry
of LYVE-1 and podoplanin. LYVE-1(+) podoplanin(+)
lymphatic vessel could not be observed and all LYVE-1(+)
c e l l sw e r ee x p r e s s e dm a c r o p h a g em a r k e r si nh u m a nc h o -
roid [73]. These ﬁndings can support observation that the
choroidcontainssomeLYVE-1(+)macrophagesandnolym-
phatics [74]. In corneal inﬂammation, LYVE-1(+) macro-
phages transdiﬀerentiate and contribute to lymphangiogen-
esis [42]. However, the role of LYVE-1(+) macrophages
has not been examined. It is unknown whether LYVE-
1(+) macrophages are vital for choroidal homeostasis or
how these cells conduct themselves in the pathological con-
dition. Because the outer choroid is recognized as an uncon-
ventionalrouteofaqueoushumoroutﬂow,choroidmayhave
lymphatic-likesystemdespitethelackofauthenticlymphatic
vessels in human.
15. Lymphatic-Targeting Therapy in
Choroidal/Uveal Disorders
Choroidal neovascularization (CNV), which involves abnor-
mal growth of blood vessels in the back of the eyes, is
a hallmark of age-related macular degeneration (AMD).
A paper reported that both VEGF-C and VEGF-D were
markedly expressed in the retinal pigment epithelium (RPE)
in a surgically removed subretinal vascular membrane of
AMD patients [75]. Because VEGF-C and VEGF-D show
angiogenic potential, they may contribute to CNV forma-
tion.Furtherinvestigationisnecessarytoestimatethecontri-
bution to AMD pathogenesis (Figure 4).
Uveitis in humans is an inﬂammatory and immune dis-
ease in the eye that causes severe vision loss [76]. The eye
is thought to have no lymphatic drainage, and the uvea
may act as an accessory lymph node during the immune re-
sponse. However, the role of lymphatic system in uveitis is
unclear (Figure 4). Because lymphatic system contributes to
the pathogenesis of immune diseases, lymphatic-targeting
drug may provide agents for uveitis treatment.
16.OcularTumor-Associated
Lymphangiogenesis
Lymphangiogenesis is observed in many types of solid tu-
mors [77]. Human cancers express various lymphangiogenic
factors including VEGF-C. Furthermore, many clinical stud-
ies showed positive correlation between VEGF-C, lymphatic
invasion, lymph node metastasis, and poor patient survival.
What about ocular tumors? A paper by Heindl et al. analyzed
the correlation of tumor-associated lymphangiogenesis and
malignancy in conjunctival squamous cell carcinoma (SCC)
[52]( Table 2, Figure 4). They observed that the development
of conjunctival SCC from premalignant stage was accom-
panied by conjunctival lymphangiogenesis. The study also
noticed that the lymphangiogenesis in tumor was associated
with an increased risk of local recurrence in patients with
SCC. Another study evaluated whether lymphangiogenesis
could contribute to the prognosis of ciliary body melanoma
with extraocular extension [53]. Intraocular lymphatic ves-
sels were found in 60% of the melanoma with extraocular
extension and the lymphangiogenesis is associated with an
increased mortality risk. However, uveal melanoma does not8 Journal of Ophthalmology
include lymphangiogenesis despite expressions of VEGF-C
and its receptor VEGFR-2 and VEGFR-3 [78]. The tumor
location, tumor type, or tumor malignancy can be a con-
tributing factor to this variation. The contribution of VEGF-
Ctotumorprogressionremainsunclear.Lymphangiogenesis
in some ocular tumors may play an important role for the
tumor progression. In the future, it will be possible that
antilymphangiogenic treatment will lower metastasis rate of
ocular tumor and mortality.
17. Ocular Drainage System
A recent paper shows that various lymphatic markers are
expressed in the human anterior segment [79]. Podoplanin
is widely accepted as a reliable lymphatic marker, because
of its continuous expression in lymphatic endothelium [80].
The immunohistochemical examination for podoplanin and
other lymphatic markers reveals that the anterior eye seg-
ment does not have lymphatic vessels. Interestingly podopla-
nin can be expressed on almost all cells of the trabecular
meshwork, endothelial cells of Schlemm’s canal, and cells of
anterior ciliary muscle tips despite the lack of lymphatics.
This suggests that the aqueous humor outﬂow tissues have
similar characteristics of lymphatic vessels (e.g., immune cell
way to lymph node). Intracameral injected ﬂuorescent anti-
gens can be observed in the ipsilateral lymph node of the
head and neck within 24 hours, suggesting that the anti-
gen in the anterior chamber reaches the lymphoid organ
[58]. This route to travel to the lymph node must be via con-
junctival lymphatic and blood circulation. Furthermore,
an alternative pathway via trabecular meshwork may exist.
Lymphatic-related molecular or cellular targeting strategies
willoﬀer novel approaches in the treatment of inﬂammatory
or immunological disorders in anterior ocular segments.
Aqueous humor drainage from the eye is known to travel via
two pathways: conventional pathway (trabecular meshwork)
andalternativepathway(uveoscleraloutﬂow)(Figure 4).Im-
pairedaqueoushumordrainageelevatesintraocularpressure
and results in glaucoma. A lymphatic outﬂow from the
eye has been considered to be absent [81]. Interestingly, a
third pathway was recently reported, “uveolymphatic path-
way” [51]( Figure 4, Table 2). Immunogold stain as well as
immunohistochemistry with podoplanin or LYVE-1 anti-
body showed lymphatic vessels in the human ciliary body
(Figure 1).Furthermore,intracamerallyinjectedtracercould
be detected in several lymph nodes (e.g., cervical lymph
node).Theuveolymphaticpathwaymaybeanoveltherapeu-
tic target for glaucoma patients.
In1989,McGetricketal.searchedforlymphaticdrainage
from monkey orbit. They injected colloid solution, or India
ink, into the retrobulbar space and examined if they could
reach the lymphatic vessels or the lymph node. However, no
lymphatic vessels could be identiﬁed in the orbit and these
tracers left the posterior orbit. This paper concluded that
the posterior pathway did not lead to the lymphatic vessels
or the lymph node [82]. From these observations, the hu-
man orbit has been thought to lack lymphatic vessels in a
long time [83]. However, in 1993, a paper using an enzy-
matic method in monkey demonstrated the presence of
lymphatic vessels in the orbital arachnoid, lacrimal gland,
extraocular muscle, and connective tissue at the orbital apex
[84]( Figure 1). In 1999, an electron microscopic study with
India ink showed that human optic nerve meninges have
lymphatic vessels [85]. These studies suggested new evidence
that cerebrospinal ﬂuid drained into lymphatics within the
meningesoftheintraorbitalpartoftheopticnerve.However,
it is unclear how lymphatics within the meninges can aﬀect
ocular disorders including glaucoma, optic neuritis, or optic
neuropathy.
18. Conclusion
Increasing evidence shows that lymphangiogenesis, as well as
angiogenesis, has a key role in ocular physiology and pathol-
ogy (Table 2). Recently antiangiogenic therapy (e.g., bevac-
izumab) is widely used for various ocular diseases. However,
various ocular disorders including edema or inﬂammation
still remain as a cause of visual loss. Better understanding of
lymphatics and lymphangiogenesis in the eye will provide a
basis for the development of novel therapeutic strategies for
incurable ocular diseases (Figure 4).
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